We are live on
!
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$633M
1-Year Est. Return
173.22%
This Fund
S&P 500
This Quarter
Est. Return
+54.87%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$491M
AUM Growth
+$145M
(+42%)
Cap. Flow
+$25.1M
Cap. Flow
% of AUM
5.1%
Top 10 Holdings %
Top 10 Hldgs %
98.81%
Holding
17
New
2
Increased
4
Reduced
4
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GH Research
GHRS
|
+$25.9M |
| 2 |
Cullinan Oncology
CGEM
|
+$10M |
| 3 |
ADC Therapeutics
ADCT
|
+$4.18M |
| 4 |
Denali Therapeutics
DNLI
|
+$3.76M |
| 5 |
Passage Bio
PASG
|
+$1.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$12.5M |
| 2 |
UPB
Upstream Bio Inc
UPB
|
+$2.41M |
| 3 |
MRUS
Merus
MRUS
|
+$2.26M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$1.88M |
| 5 |
iBio
IBIO
|
+$371K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $144M | 29.4% |
1,534,141
-34,700
| -2% | -$2.26M |
|
2
Stoke Therapeutics
STOK
$1.8B
| $110M | 22.37% |
5,404,674
| – | – |
|
|
3
GH Research
GHRS
$1.93B
| $104M | 21.23% |
8,601,189
+1,854,238
| +27% | +$25.9M |
|
|
4
Protagonist Therapeutics
PTGX
$8.79B
| $46.5M | 9.47% |
700,014
-33,000
| -5% | -$1.88M |
|
|
5
Cullinan Oncology
CGEM
$1.01B
| $34.2M | 6.96% |
5,766,090
+1,365,248
| +31% | +$10M |
|
6
C4 Therapeutics
CCCC
$385M
| $15.8M | 3.21% |
7,098,133
| – | – |
|
7
TScan Therapeutics
TCRX
$48.6M
| $14.3M | 2.91% |
7,857,347
| – | – |
|
8
Precision BioSciences
DTIL
$180M
| $5.76M | 1.17% |
1,042,596
+6,545
| +0.6% | +$31.3K |
|
|
9
ADC Therapeutics
ADCT
$134M
| $5.3M | 1.08% |
+1,325,848
| New | +$4.18M |
|
|
10
Passage Bio
PASG
$14.4M
| $5.01M | 1.02% |
623,704
+160,856
| +35% | +$1.12M |
|
|
11
Denali Therapeutics
DNLI
$3.65B
| $3.8M | 0.77% |
+261,687
| New | +$3.76M |
|
|
12
iBio
IBIO
$69.5M
| $874K | 0.18% |
1,055,897
-482,676
| -31% | -$371K |
|
|
13
Allogene Therapeutics
ALLO
$649M
| $677K | 0.14% |
546,119
-10,510,890
| -95% | -$12.5M |
|
14
Design Therapeutics
DSGN
$761M
| $497K | 0.1% |
65,954
| – | – |
|
15
Assembly Biosciences
ASMB
$498M
| – | – |
-10,366
| Closed | -$188K |
|
|
UPB
16
Upstream Bio Inc
UPB
$343M
| – | – |
-219,247
| Closed | -$2.41M |
|
|
NEUP
17
Neuphoria Therapeutics
NEUP
$21M
| – | – |
-45,806
| Closed | -$325K |
|
Similar funds
RFA
WA
AMM
EIM
SWP
ACM
BI
SIC
Lynx1 Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Lynx1 Capital Management held 17 positions worth $491M, up 42% from $346M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Lynx1 Capital Management deployed $25.1M of net new capital in Q3 2025, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was ADC Therapeutics: 1,325,848 shares worth $5.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Allogene Therapeutics, an estimated $12.5M trimmed.
- Lynx1 Capital Management's largest Q3 2025 buy was ADC Therapeutics: 1,325,848 shares worth $5.3M.
- Lynx1 Capital Management added most to GH Research in Q3 2025, an estimated $25.9M increase.
- Lynx1 Capital Management's biggest Q3 2025 reduction was Allogene Therapeutics, cutting an estimated $12.5M.
- Lynx1 Capital Management fully exited Upstream Bio Inc in Q3 2025, selling an estimated $2.41M.
- Lynx1 Capital Management's ten largest holdings make up 99% of its $491M portfolio in Q3 2025.
- Lynx1 Capital Management opened 2 new positions and closed 3 in Q3 2025.
- Lynx1 Capital Management's portfolio value rose 42% quarter-over-quarter to $491M.
Based on Lynx1 Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.